Myocyte-dependent Regulation of Endothelial Cell Syndecan-4 Expression
ROLE OF TNF-alpha *

Yufeng ZhangDagger , Manolis Pasparakis§, George Kollias§, and Michael SimonsDagger

From the Dagger  Angiogenesis Research Center, Cardiovascular Division, Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachussetts 02215 and the § Laboratory of Molecular Genetics, Hellenic Pasteur Institute, Athens 115 21, Greece

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Syndecan-4 is a unique member of the syndecan gene family that has the ability to bind and activate protein kinase C-alpha . Whereas increased syndecan-4 levels have been noted in ischemic hearts, little is known regarding the regulation of its expression. To investigate the role of cardiac myocytes in induction of syndecan-4 expression, human endothelial cells (ECV304) were exposed to a medium conditioned by primary mouse cardiac myocytes or H9c2 cells. The medium conditioned by hypoxic but not normal myocytes was able to induce syndecan-4 expression in ECV cells. Western analysis of the conditioned medium demonstrated an increased presence of tumor necrosis factor-alpha (TNF-alpha ) in the medium conditioned by hypoxic but not normal myoblasts. Primary cardiac myocytes collected from the wild type C57/129 but not the homozygous TNF-alpha -/- knockout mice were able to induce syndecan-4 expression in ECV cells when cultured under hypoxic conditions. In vitro studies demonstrated that TNF-alpha induced endothelial cell syndecan-4 expression by both increasing syndecan-4 gene expression in an NF-kappa B-dependent manner and by prolonging syndecan-4 mRNA half-life. We conclude that TNF-alpha is the principal factor produced by the ischemic myocytes that is responsible for induction of endothelial cell syndecan-4 expression and that this requires both transcriptional and posttranscriptional mechanisms.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Syndecan-4 is one of the principal heparin sulfate-carrying proteins on the cell surface (1). It is expressed by a number of different cell types including endothelial cells, smooth muscle cells, and cardiac myocytes, although expression in quiescent tissues is fairly low. Syndecans can participate in a variety of biological functions including regulation of blood coagulation, cell adhesion, and low density lipoprotein transport (2, 3). In addition to these activities shared by all syndecans, syndecan-4 cytoplasmic domain can bind to and activate protein kinase C-alpha with the degree of activation regulated by the extent of syndecan-4 cytoplasmic tail phosphorylation (4-7).

Despite these interesting properties, little is known about the regulation of syndecan-4 gene expression. Its levels are increased after various forms of tissue injury including skin wounds (8), vascular wall injury (9), or myocardial infarction (10). The increase in syndecan-4 expression in skin wounds and in the heart following myocardial infarction has been ascribed to the presence of a proline-arginine-rich peptide, PR39. No other factors responsible for this increase have been identified (8, 10). The present study was designed to study the role of cardiac myocytes in the induction of syndecan-4 expression under normal and ischemic (hypoxic) conditions. To this end, we determined the ability of myocyte- or myoblast-conditioned medium to induce syndecan-4 expression in a human endothelial cell line. We find that TNF-alpha 1 secreted by hypoxic but not normal myocytes is able to induce syndecan-4 expression and that the mechanism of this induction involves both transcriptional activation of syndecan-4 gene expression and posttranscriptional regulation of syndecan-4 message half-life.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Cell Culture-- A human umbilical endothelial cell line, ECV304 (ATCC), was cultured in M199 medium supplemented with 10% fetal bovine serum (FBS), 100 units/ml penicillin, and 100 µg/ml streptomycin. A rat cardiac myoblast cell line, H9c2 (ATCC), was cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS and penicillin/streptomycin. IC-21 (ATCC), a mouse macrophage cell line, was cultured in RPMI 1640 medium supplemented with 10% FBS.

Cardiac myocytes were isolated from day 2 neonatal C57/129 or same background TNF-alpha -/- mice (11). A total of 24 hearts from each mouse strain was used. At sacrifice the hearts were removed aseptically, cut into 1-2-mm pieces, placed in ice-cold Hanks' balanced saline solution without either Ca2+ or Mg2+, and subjected to serial digestions with 0.5 mg/ml collagenase II (Worthington), 0.1% trypsin, 15 µg/ml DNase I, and 1% chicken serum at 37 °C with constant rotation. Supernatant was collected every 10-15 min, and digestion was stopped by addition of 10% horse serum. Dissociated cells were collected by centrifugation and resuspended in DMEM/F12 medium supplemented with 5% horse serum, 2 g/liter bovine serum albumin (fraction V), 3 mM pyruvic acid, 15 mM HEPES (pH 7.6), 100 µM ascorbic acid, 100 units/ml penicillin, 100 µg/ml streptomycin, 4 µg/ml transferrin, 0.7 ng/ml sodium selenium, and 5 µg/ml linoleic acid for 1 h to enrich for myocytes. The suspension was then plated onto 1% gelatin-coated dishes at 2.5 × 106 cells/60-mm dish. Bromodeoxyuridine (0.1 mM) was added to prevent proliferation of non-myocytes. Horse serum and bromodeoxyuridine were removed from the medium after 36 h.

Growth Factor Studies-- For determination of growth factor responsiveness of syndecan-4 expression, ECV304 cells were cultured in 10% FBS-DMEM to 80% confluence. At that point the cells were washed with PBS, the medium was replaced with serum-free DMEM for 6 h, and then one of the following growth factors was added: hrVEGF165 (25 ng/ml, Genentech, Inc.), hrbFGF (25 ng/ml, Chiron Corp.), hrPDGF-AA (20 ng/ml, Sigma) or hrPDGF-AB (20 ng/ml, Sigma), hrTGF-beta (20 ng/ml, R&D Systems), hrTNF-alpha (20 ng/ml, Sigma), or mouse epidermal growth factor (20 ng/ml, Becton Dickinson Labware). Cells were harvested and total RNA was extracted after 24 h and subjected to Northern blot analysis.

Preparation of Myoblast- or Myocyte-conditioned Medium-- H9c2 cells were cultured in DMEM supplemented with 10% FBS in 100-mm dishes to 90% confluence. At that point, the cells were washed three times with PBS and the medium was changed to serum-free DMEM. Following 24 h of culture under hypoxic (0-2% O2) or normal oxygen conditions, the medium was collected, centrifuged for 10 min at 2000 × g to remove debris, and then stored at -80 °C for further use. Similar procedures were used for collection of myocyte-conditioned medium.

Analysis of Syndecan-4 Expression-- For Northern analysis, total RNA extracted from cultured cells with Tri Reagent (Sigma) was fractionated on 1.2% formaldehyde-agarose gel and transferred onto GeneScreen Plus membrane. cDNA probes for human syndecan-4 or glyceraldehyde-3-phosphate dehydrogenase were labeled with alpha -[32P]dCTP using a random priming kit (Roche Molecular Biochemicals), and hybridization was carried out for 3 h at 65 °C in Quickhyb solution (Strategene), followed by serial washes with 0.1× SSC, 0.1% SDS at room temperature for 15 min, 45 °C for 15 min, and 65 °C for 15 min. The quantitative analysis of hybridization signal was carried out using PhosphorImager (Molecular Dynamics) and ImageQuant software. RNA loading was adjusted using ethidium bromide gel 18 S RNA signal or glyceraldehyde-3-phosphate dehydrogenase expression level.

For determination of syndecan-4 protein levels, ECV cells were washed with PBS (137 mM NaCl, 10 mM Na2HPO4, 3.6 mM KCl, 1.8 mM KH2PO4 (pH 7.4)), dissociated by 0.05% trypsin, 0.5 mM EDTA (Life Technologies, Inc.) in PBS for 10 min at 37 °C, and sedimented by 200 × g centrifugation at 4 °C for 5 min. Western blotting was carried out with anti-syndecan-4 cytoplasmic domain antibody following SDS-polyacrylamide gel electrophoresis of the total cell protein extract as described previously (6).

Western Blot Analysis of TNF-alpha in Myoblast-conditioned Medium-- Conditioned medium collected from five 100-mm Petri dishes of confluent H9c2 cells cultured for 48 h under hypoxic or normal conditions was concentrated using Centriprep followed by Centricon columns (Amicon, Inc.) to a final volume of 80 µl. Aliquots of the concentrated material (20 µl) were subjected to 10% SDS-polyacrylamide gel electrophoresis and transferred to an ImmobilonTM-P membrane (Millipore), and the blot was then incubated with a polyclonal goat anti-rat TNF-alpha antibody (1:200 dilution, Santa Cruz Biotechnology) in PBS supplemented with 5% nonfat milk overnight at 4 °C. An ECL system (Amersham Pharmacia Biotech) was used to detect the signal.

Syndecan-4 mRNA Stability Assay-- 100 µM 5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole was added to ECV304 cells following overnight culture in 0.5% FBS-M199. The cells were then harvested at the indicated time points and total RNA was extracted as described above. 10 µg of total RNA for each time point were subjected to Northern blot analysis with a syndecan-4 cDNA probe. Signal was quantified using PhosphorImager with RNA loading adjusted by glyceraldehyde-3-phosphate dehydrogenase levels. The mRNA half-life was calculated using the formula t1/2 = ln2/(mRNA decay rate constant) with the decay rate constant derived from the slope of the decay curve.

Syndecan-4 Transcription Studies-- A 715-nucleotide fragment (-690 to +25 nucleotide of the murine sequence) encompassing the basal elements of mouse syndecan-4 promoter (courtesy of Dr. T. Kojima, Nagoya University) was cloned into a pGL-3 vector (Promega) containing the luciferase reporter construct. The syndecan-4 promoter construct and a pGRE-Neo (U. S. Biochemical Corp.) construct were linearized and, following phenol/chloroform purification, used for electroporation. To this end, ECV304 cells were trypsinized and washed twice with a fresh medium; 6 × 106 of cells in 0.75 ml of medium were incubated with 30 µg of syndecan-4 promoter-containing pGL-3 and 3 µg of pGRE-Neo linearized plasmids for 5 min on ice in a 0.4-cm cuvette. Electroporation was carried out at 290 V, 600 microfarads using Gene Pulser II (Bio-Rad). Following electroporation, the cells were quickly diluted with the fresh M199 medium containing 10% FBS supplemented with 5 mM sodium butyrate and plated onto a 100-mm Petri dish. Sodium butyrate was removed after overnight exposure, and the culture was continued for another 36 h in 10% FBS-M199. The cells were then passaged into two dishes and cultured in medium containing 1 mg/ml G418 (Life Technologies, Inc.). All colonies were pooled together after 10 days and maintained in the selection medium.

For promoter studies, cells stably expressing syndecan-4 promoter construct were plated onto 12-well plates and allowed to come to 80% confluence in 10% FBS-M199 medium. The medium was then changed to 0.5% FBS-M199 overnight. TNF-alpha was added at the indicated concentration. After 6 h of exposure, cells were lysed, and luciferase activity was determined using the luciferase assay system (Promega).

To assess the role of NF-kappa B in the TNF-alpha -dependent stimulation of syndecan-4 gene expression, ECV304 cells plated on 60-mm dishes were cultured until 90% confluence and subjected to serum starvation overnight. Lactacystin (Calbiochem) was then added to medium at a concentration of 10 µM. 1 h later, TNF-alpha (20 ng/ml) was added. Syndecan-4 mRNA levels were determined using Northern blot analysis 4 h after exposure of lactacystin-treated or control cells to TNF-alpha (20 ng/ml).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Induction of Syndecan-4 Expression in Endothelial Cells by Hypoxic Myoblast Cell-conditioned Medium-- To investigate the role of myocyte-endothelial cell interaction in the regulation of syndecan-4 expression in endothelial cells, we studied the ability of myoblast- or cardiac myocyte-conditioned medium to induce syndecan-4 expression in ECV304 cells. Exposure of ECV304 cells to the medium conditioned by the H9c2 cells cultured under normal conditions did not affect syndecan-4 expression. However, medium conditioned by H9c2 cells cultured under hypoxic conditions produced a nearly 2-fold increase in syndecan-4 mRNA expression in ECV304 cells and a 2.5-fold increase in syndecan protein (Fig. 1). These results suggested that myoblasts exposed to hypoxia secreted a factor that was responsible for induction of syndecan-4 expression. To determine whether any of the known myoblast-secreted growth factors were responsible for this event, ECV304 cells were exposed to a panel of cytokines. Of the growth factors tested, only TNF-alpha was able to induce syndecan-4 expression in ECV304 cells (Fig. 2) in a dose-dependent manner. The induction of syndecan-4 mRNA expression by TNF-alpha was prompt, beginning at 1 h, reaching maximal effect at 3 h (Fig. 2), and lasting for at least 24 h (data not shown).


View larger version (32K):
[in this window]
[in a new window]
 
Fig. 1.   Effects of H9c2-conditioned medium on syndecan-4 expression in ECV304 cells. Syndecan-4 gene expression in ECV304 cells was assessed after 24 h of exposure to the medium conditioned by hypoxic (lane 2) or normal (lane 3) H9c2 myoblasts using Northern (A) or Western (B) blotting. Note a significant induction in syndecan-4 mRNA and protein expression by medium conditioned by hypoxic but not normal H9c2 cells. C, graphic representation of the effects of H9c2-conditioned medium on syndecan-4 mRNA and protein expression. Syndecan-4 mRNA levels are expressed as percent control (mean of two determinations). Black bars, mRNA levels; striped bars, protein levels; H9c2-CM, H9c2 myocyte-conditioned medium.


View larger version (34K):
[in this window]
[in a new window]
 
Fig. 2.   Role of TNF-alpha in induction of syndecan-4 expression. A, growth factor induction of syndecan-4 expression. Subconfluent serum-starved ECV304 cells were treated with either vascular endothelial growth factor (VEGF, 25 ng/ml), basic fibroblast growth factor (bFGF, 25 ng/ml), platelet-derived growth factor-AA (PDGF-AA, 20 ng/ml), platelet-derived growth factor-AB (PDGF-AB, 20 ng/ml), transforming growth factor-beta (TGF-beta , 20 ng/ml), TNF-alpha (20 ng/ml), or epidermal growth factor (EGF) (20 ng/ml). Total RNA was harvested after 24 h and subjected to Northern analysis for syndecan-4 expression. B and D, time course of TNF-alpha -mediated induction of syndecan-4 expression. Subconfluent serum-starved ECV304 cells were treated with 20 ng/ml TNF-alpha and subjected to Northern (B) or Western (D) blotting with anti-syndecan-4 cytoplasmic domain antibody at indicated time points. C and E, dose response of TNF-alpha -dependent induction of syndecan-4 expression. Indicated amounts of recombinant TNF-alpha were added to subconfluent ECV304 cells, and syndecan-4 mRNA (C) and protein levels (E) were determined 6 h later. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.

TNF-alpha Is a Primary Factor Responsible for Induction of Syndecan-4 Expression by Myoblasts-- To demonstrate that TNF-alpha is produced by hypoxic myoblasts, cell culture medium conditioned by H9c2 cells under normal and hypoxic conditions was subjected to Western analysis with anti-TNF-alpha antibody. Cell lysate of IC-21 cells, a macrophage cell line known to produce large amounts of TNF-alpha under normal culture conditions, was used as a control. The presence of secreted TNF-alpha was detected in IC-21 cell lysate and in H9c2 cells cultured under hypoxic conditions. Compared with the hypoxic H9c2 cell-conditioned medium, only a trace amount of TNF-alpha was detected in the medium conditioned by the normal H9c2 cells (Fig. 3A). To confirm that TNF-alpha is the primary factor responsible for myoblast-dependent induction of syndecan-4 expression, we used primary myocyte cultures from homozygous TNF-alpha knockout mice and age-matched controls to condition serum-free medium in the manner similar to the H9c2 experiments. Cell culture media conditioned by primary myocytes derived from either the TNF-alpha -/- or wild type C57/129 mice cultured under normal conditions did not induce endothelial cell syndecan-4 mRNA expression. However, medium conditioned by hypoxic myocytes from the C57/129 but not TNF-alpha -/- mice induced syndecan-4 expression to the extent similar to that seen with hypoxic H9c2 cells (Fig. 3B).


View larger version (17K):
[in this window]
[in a new window]
 
Fig. 3.   TNF-alpha produced by ischemic myocytes is the primary factor responsible for induction of syndecan-4 expression. A, Western blot analysis of secreted TNF-alpha protein in medium conditioned by H9c2 cells cultured under normal or hypoxic conditions. Note the increased presence of TNF-alpha in the medium conditioned by hypoxic (lane 3) but not normal (lane 2) H9c2 cells. IC-21 cell lysate (lane 1) was used as a control. B, to demonstrate the dominant role of TNF-alpha in induction of syndecan-4 expression, primary myocytes isolated from neonatal hearts of TNF-alpha knockout (TNF-alpha -/-) and age-matched control (TNF-alpha +/+) mice were used to condition medium during culture under normal or hypoxic conditions. Northern analysis of syndecan-4 expression in ECV304 cells 24 h after exposure to conditioned medium demonstrated increased syndecan-4 levels only in cells exposed to the medium conditioned by hypoxic myocytes from control mice (B, top). A graphic representation of syndecan-4 mRNA expression level after normalization for 18 S RNA ribosomal band is shown (B, bottom). All results are expressed as percent control (syndecan-4 levels in ECV cells prior to any exposure).

Mechanism of TNF-alpha -mediated Induction of Syndecan-4 Expression-- To determine whether TNF-alpha regulates syndecan-4 gene expression by transcriptional or posttranscriptional mechanisms, we measured syndecan-4 mRNA half-life in ECV304 cells in the presence or absence of TNF-alpha treatment. Exposure to TNF-alpha at 20 ng/ml increased syndecan-4 mRNA half-life from 16 to 24 h (Fig. 4A). To assess the effect of TNF-alpha on syndecan-4 gene transcription, we measured activity of a luciferase construct under control of the mouse syndecan-4 promoter. Exposure of the pooled population of ECV304 cells stably transfected with this construct to TNF-alpha at 20 ng/ml led to a 2-fold increase in luciferase activity (Fig. 4B). Because TNF-alpha is known to activate gene expression in an NF-kappa B-dependent manner and given that syndecan-4 promoter contains an NF-kappa B-binding site, we examined the effect of inhibition of NF-kappa B-dependent transcription on the ability of TNF-alpha to induce syndecan-4 expression. Pretreatment with lactacystin, an inhibitor of proteasome-dependent degradation of Ikappa Balpha expression, completely blocked TNF-alpha -induced activation of syndecan-4 expression (Fig. 5). These results indicate that TNF-alpha regulates syndecan-4 expression at both transcriptional and posttranscriptional levels.


View larger version (22K):
[in this window]
[in a new window]
 
Fig. 4.   Mechanism of TNF-alpha -induced increase in syndecan-4 expression in ECV cells. A, to assess the effect of TNF-alpha administration on syndecan-4 mRNA half-life, ECV304 cells were cultured with or without TNF-alpha (20 ng/ml). Following overnight exposure, 5,6-dichloro-1-beta -D-ribofuranosylbenzimidazole, at a concentration of 100 µM, was added. At indicated time points, the cells were harvested and subjected to Northern blot analysis for syndecan-4 expression. Signal was quantified using PhosphorImager with RNA loading adjusted for glyceraldehyde-3-phosphate dehydrogenase levels. Note the substantially prolonged syndecan-4 mRNA half-life in TNF-alpha -treated cells. B, to assess the effects of TNF-alpha administration on syndecan-4 promoter activity in ECV304 cells, we conducted an analysis of luciferase activity in pools of ECV cells stably transfected with a construct containing mouse syndecan-4 basic promoter fragment (-690 to +25 nucleotide) linked to a luciferase gene. Note a 2-fold increase in luciferase activity following TNF-alpha treatment (mean ± standard deviation, p < 0.01 TNF-alpha treatment versus control). GAPDH, glyceraldehyde-3-phosphate dehydrogenase.


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 5.   TNF-alpha induces syndecan-4 gene expression in an NF-kappa B-dependent manner. To study the role of NF-kappa B-dependent gene transcription in TNF-alpha -induced activation of syndecan-4 expression, ECV304 cells were exposed to TNF-alpha (20 ng/ml) in the absence of lactacystin (TNF-alpha ) or following 1 h pretreatment with lactacystin (LC+TNF-alpha ). Note the increased syndecan-4 expression in TNF-alpha -treated cells that were blocked by pretreatment with lactacystin. Addition of lactacystin by itself (LC) had no effect on base-line syndecan-4 levels. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

The principal finding of this study is that TNF-alpha , secreted by hypoxic but not normal myocytes, is able to increase syndecan-4 expression in endothelial cells. A number of findings point to TNF-alpha as the main factor responsible for the ability of hypoxic myocyte-conditioned medium to induce syndecan-4 expression. First, the cytokine is capable of increasing syndecan-4 mRNA levels in a dose-dependent manner and with an appropriate time course. Second, TNF-alpha is present in medium conditioned by hypoxic but not normal myoblasts. Finally, medium conditioned by myocytes cultured under either normal or hypoxic conditions derived from the TNF-alpha knockout mice fails to induce syndecan-4 expression.

TNF-alpha -dependent activation of syndecan-4 expression involves both transcriptional and posttranscriptional events. The study of syndecan-4 transcription was carried out using a mixture of approximately 200 independent stable clones, thus eliminating artifacts potentially associated with the expression construct integration into hyper- or hypoactive regions of the genome. The promoter fragment used was previously shown to possess basal promoter activity (12), although it is possible that additional control elements were missing. The degree of induction of the luciferase expression was similar to the extent of increase in the endogenous syndecan-4 mRNA level in TNF-alpha -treated ECV304 cells. Taken together, the extent of transcriptional activation as measured in luciferase assays and prolongation of mRNA half-life closely parallel the increase in endogenous syndecan-4 protein levels in these cells following TNF-alpha exposure.

TNF-alpha is thought to regulate gene expression by inducing degradation of a transcriptional inhibitor, Ikappa Balpha , thus allowing the p50 NF-kappa B·RelA complex to bind to its nuclear binding sites and activate gene expression (13). Basal syndecan-4 promoter possesses an NF-kappa B binding site (GGGGGAATT, nucleotides -84 to -76 of the mouse sequence). Therefore, it is possible that syndecan-4 gene expression up-regulation by TNF-alpha occurs, at least in part, via the NF-kappa B-dependent pathway. To confirm this, we exposed ECV304 cells to TNF-alpha following pretreatment with lactacystin. Lactacystin is a specific inhibitor of proteasome function (14) and, in particular, is known to block proteasome-dependent degradation of Ikappa Balpha . In accordance with these considerations, we found that pretreatment with lactacystin completely blocked the ability of TNF-alpha to induce syndecan-4 expression.

Recent studies have suggested that syndecan-4 plays an important role in regulation of endothelial cell growth and migration and in basic fibroblast growth factor-dependent signaling (4, 5, 7). Studies in our laboratory have suggested that increased syndecan-4 expression augmented the ability of endothelial cells to migrate, proliferate, and form vascular structures in Matrigel in response to basic fibroblast growth factor.2 Thus, the ability of TNF-alpha to induce syndecan-4 expression while suppressing that of syndecan-1 (15) may lead to enhanced endothelial cell growth.

TNF-alpha is a potent angiogenic factor in a number of in vitro and in vivo systems (16, 17). The cytokine expression in the heart is induced by myocardial ischemia (18, 19), and the presence of secreted TNF-alpha has been demonstrated in an in vitro model (20). Whereas TNF-alpha has a wide range of biological activities, its ability to induce syndecan-4 expression may play a particularly important role in mediation of its angiogenic activity.

In summary, ischemic myocytes can induce syndecan-4 expression in surrounding endothelial cells by paracrine secretion of TNF-alpha . This mechanism may play an important role in myocyte-dependent regulation of endothelial cell activity and the ability of ischemic tissues to initiate and propagate an angiogenic response.

    FOOTNOTES

* This paper was supported in part by National Institutes of Health Grants R01 HL53793 and P50 HL56993 (to M. S.) and by a grant from Chiron Corp.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

To whom correspondence should be addressed: Cardiovascular Division, Beth Israel Deaconess Medical Center, 330 Brookline Ave., Boston, MA 02215. Tel.: 617-667-5364; Fax: 617-975-5201; E-mail: msimons{at}bidmc.harvard.edu.

2 R. Volk and M. Simons, unpublished observations.

    ABBREVIATIONS

The abbreviations used are: TNF-alpha , tumor necrosis factor-alpha ; FBS, fetal bovine serum; PBS, phosphate-buffered saline; DMEM, Dulbecco's modified Eagle's medium; NF-kappa B, nuclear factor-kappa B.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Kojima, T., Shworak, N. W., and Rosenberg, R. D. (1992) J. Biol. Chem. 267, 4870-4877[Abstract/Free Full Text]
  2. Carey, D. J. (1997) Biochem. J. 327, 1-16[Medline] [Order article via Infotrieve]
  3. Rosenberg, R. D., Shworak, N. W., Liu, J., Schwartz, J. J., and Zhang, L. (1997) J. Clin. Invest. 99, 2062-2070[Free Full Text]
  4. Oh, E. S., Woods, A., and Couchman, J. R. (1997) J. Biol. Chem. 272, 8133-8136[Abstract/Free Full Text]
  5. Oh, E. S., Woods, A., and Couchman, J. R. (1997) J. Biol. Chem. 272, 11805-11811[Abstract/Free Full Text]
  6. Horowitz, A., and Simons, M. (1998) J. Biol. Chem. 273, 10914-10918[Abstract/Free Full Text]
  7. Horowitz, A., and Simons, M. (1998) J. Biol. Chem. 273, 25548-25551[Abstract/Free Full Text]
  8. Gallo, R. L., Ono, M., Povsic, T., Page, C., Eriksson, E., Klagsburn, M., and Bernfield, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 11035-11039[Abstract/Free Full Text]
  9. Nikkari, S. T., Jarvelainen, H. T., Wight, T. N., Ferguson, M., and Clowes, A. W. (1994) Am. J. Pathol. 144, 1348-1356[Abstract]
  10. Li, J., Brown, L. F., Laham, R. J., Volk, R., and Simons, M. (1997) Circ. Res. 81, 785-796[Abstract/Free Full Text]
  11. Pasparakis, M., Alexopoulou, L., Episkopou, V., and Kollias, G. (1996) J. Exp. Med. 184, 1397-1411[Abstract]
  12. Tsuzuki, S., Kojima, T., Katsumi, A., Yamazaki, T., Sugiura, I., and Saito, H. (1997) J. Biochem. (Tokyo) 122, 17-24[Abstract]
  13. Whiteside, S. T., and Israel, A. (1997) Semin. Cancer Biol. 8, 75-82[CrossRef][Medline] [Order article via Infotrieve]
  14. Fenteany, G., and Schreiber, S. L. (1998) J. Biol. Chem. 273, 8545-8548[Free Full Text]
  15. Kainulainen, V., Nelimarkka, L., Jarvelainen, H., Laato, M., Jalkanen, M., and Elenius, K. (1996) J. Biol. Chem. 271, 18759-18766[Abstract/Free Full Text]
  16. Montrucchio, G., Lupia, E., Battaglia, E., Passerini, G., Bussolino, F., Emanuelli, G., and Camussi, G. (1994) J. Exp. Med. 180, 377-382[Abstract]
  17. Norrby, K. (1996) Microvasc. Res. 52, 79-83[CrossRef][Medline] [Order article via Infotrieve]
  18. Chandrasekar, B., Colston, J. T., and Freeman, G. L. (1997) Clin. Exp. Immunol. 108, 346-351[Medline] [Order article via Infotrieve]
  19. Meldrum, D. R. (1998) Am. J. Physiol. 274, R577-595[Medline] [Order article via Infotrieve]
  20. Gurevitch, J., Frolkis, I., Yuhas, Y., Paz, Y., Matsa, M., Mohr, R., and Yakirevich, V. (1996) J. Am. Coll. Cardiol. 28, 247-252[CrossRef][Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.